5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Interleukin-1 O
blockade O
may O
interfere O
with O
immune O
response O
to O
infections O
. O

Serious O
, O
life-threatening O
infections O
have O
been O
reported O
in O
patients O
taking O
ARCALYST O
. O

Discontinue O
treatment O
with O
ARCALYST O
if O
a O
patient O
develops O
a O
serious O
infection O
. O

Do O
not O
initiate O
treatment O
with O
ARCALYST O
in O
patients O
with O
active O
or O
chronic O
infections O
. O

( O
5.1 O
) O
* O
Hypersensitivity O
reactions O
associated O
with O
ARCALYST O
administration O
have O
been O
rare O
. O

If O
a O
hypersensitivity O
reaction O
occurs O
, O
discontinue O
administration O
of O
ARCALYST O
and O
initiate O
appropriate O
therapy O
. O

( O
5.5 O
) O
* O
Live O
vaccines O
should O
not O
be O
given O
concurrently O
with O
ARCALYST O
. O

Prior O
to O
initiation O
of O
therapy O
with O
ARCALYST O
, O
patients O
should O
receive O
all O
recommended O
vaccinations O
. O

( O
5.3 O
) O
5.1 O
Infections O
Interleukin O
-1 O
( O
IL-1 O
) O
blockade O
may O
interfere O
with O
the O
immune O
response O
to O
infections B-OSE_Labeled_AE
. O

Treatment O
with O
another O
medication O
that O
works O
through O
inhibition O
of O
IL-1 O
has O
been O
associated O
with O
an O
increased O
risk O
of O
serious O
infections B-NonOSE_AE
, O
and O
serious O
infections B-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
taking O
ARCALYST O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

There O
was O
a O
greater O
incidence O
of O
infections B-OSE_Labeled_AE
in O
patients O
on O
ARCALYST O
compared O
with O
placebo O
. O

In O
the O
controlled O
portion O
of O
the O
study O
, O
one O
infection B-OSE_Labeled_AE
was O
reported O
as O
severe O
, O
which O
was O
bronchitis B-OSE_Labeled_AE
in O
a O
patient O
on O
ARCALYST O
. O

In O
an O
open-label O
extension O
study O
, O
one O
patient O
developed O
bacterial B-OSE_Labeled_AE
meningitis I-OSE_Labeled_AE
and O
died B-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.3 O
) O
] O
. O

ARCALYST O
should O
be O
discontinued O
if O
a O
patient O
develops O
a O
serious O
infection B-NonOSE_AE
. O

Treatment O
with O
ARCALYST O
should O
not O
be O
initiated O
in O
patients O
with O
an O
active O
or O
chronic O
infection B-NonOSE_AE
. O

In O
clinical O
studies O
, O
ARCALYST O
has O
not O
been O
administered O
concomitantly O
with O
tumor O
necrosis O
factor O
( O
TNF O
) O
inhibitors O
. O

An O
increased O
incidence O
of O
serious O
infections B-NonOSE_AE
has O
been O
associated O
with O
administration O
of O
an O
IL-1 O
blocker O
in O
combination O
with O
TNF O
inhibitors O
. O

Taking O
ARCALYST O
with O
TNF O
inhibitors O
is O
not O
recommended O
because O
this O
may O
increase O
the O
risk O
of O
serious O
infections B-NonOSE_AE
. O

Drugs O
that O
affect O
the O
immune O
system O
by O
blocking O
TNF O
have O
been O
associated O
with O
an O
increased O
risk O
of O
reactivation B-NonOSE_AE
of I-NonOSE_AE
latent I-NonOSE_AE
tuberculosis I-NonOSE_AE
( I-NonOSE_AE
TB I-NonOSE_AE
) O
. O

It O
is O
possible O
that O
taking O
drugs O
such O
as O
ARCALYST O
that O
block O
IL-1 O
increases O
the O
risk O
of O
TB B-NonOSE_AE
or O
other O
atypical O
or O
opportunistic B-NonOSE_AE
infections I-NonOSE_AE
. O

Healthcare O
providers O
should O
follow O
current O
CDC O
guidelines O
both O
to O
evaluate O
for O
and O
to O
treat O
possible O
latent B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
infections I-Not_AE_Candidate
before O
initiating O
therapy O
with O
ARCALYST O
. O

5.2 O
Immunosuppression O
The O
impact O
of O
treatment O
with O
ARCALYST O
on O
active B-Not_AE_Candidate
and/or O
chronic O
infections I-Not_AE_Candidate
and O
the O
development O
of O
malignancies B-NonOSE_AE
is O
not O
known O
[ O
see O
Adverse O
Reactions O
( O
6.3 O
) O
] O
. O

However O
, O
treatment O
with O
immunosuppressants O
, O
including O
ARCALYST O
, O
may O
result O
in O
an O
increase O
in O
the O
risk O
of O
malignancies B-OSE_Labeled_AE
. O

5.3 O
Immunizations O
Since O
no O
data O
are O
available O
on O
either O
the O
efficacy O
of O
live O
vaccines O
or O
on O
the O
risks O
of O
secondary B-NonOSE_AE
transmission I-NonOSE_AE
of I-NonOSE_AE
infection I-NonOSE_AE
by O
live O
vaccines O
in O
patients O
receiving O
ARCALYST O
, O
live O
vaccines O
should O
not O
be O
given O
concurrently O
with O
ARCALYST O
. O

In O
addition O
, O
because O
ARCALYST O
may O
interfere B-NonOSE_AE
with I-NonOSE_AE
normal I-NonOSE_AE
immune I-NonOSE_AE
response I-NonOSE_AE
to I-NonOSE_AE
new I-NonOSE_AE
antigens I-NonOSE_AE
, O
vaccinations O
may O
not O
be O
effective O
in O
patients O
receiving O
ARCALYST O
. O

No O
data O
are O
available O
on O
the O
effectiveness O
of O
vaccination O
with O
inactivated O
( O
killed O
) O
antigens O
in O
patients O
receiving O
ARCALYST O
. O

Because O
IL-1 O
blockade O
may O
interfere B-NonOSE_AE
with I-NonOSE_AE
immune I-NonOSE_AE
response I-NonOSE_AE
to I-NonOSE_AE
infections I-NonOSE_AE
, O
it O
is O
recommended O
that O
prior O
to O
initiation O
of O
therapy O
with O
ARCALYST O
adult O
and O
pediatric O
patients O
receive O
all O
recommended O
vaccinations O
, O
as O
appropriate O
, O
including O
pneumococcal O
vaccine O
and O
inactivated O
influenza O
vaccine O
. O

( O
See O
current O
Recommended O
Immunizations O
schedules O
at O
the O
website O
of O
the O
Centers O
for O
Disease O
Control O
. O

http O
: O
//www.cdc.gov/vaccines/recs/schedules/ O
) O
. O

5.4 O
Lipid O
Profile O
Changes O
Patients O
should O
be O
monitored O
for O
changes B-NonOSE_AE
in I-NonOSE_AE
their I-NonOSE_AE
lipid I-NonOSE_AE
profiles I-NonOSE_AE
and O
provided O
with O
medical O
treatment O
if O
warranted O
[ O
see O
Adverse O
Reactions O
( O
6.7 O
) O
] O
. O

5.5 O
Hypersensitivity O
Hypersensitivity B-OSE_Labeled_AE
reactions O
associated O
with O
ARCALYST O
administration O
in O
the O
clinical O
studies O
were O
rare O
. O

If O
a O
hypersensitivity B-NonOSE_AE
reaction I-NonOSE_AE
occurs O
, O
administration O
of O
ARCALYST O
should O
be O
discontinued O
and O
appropriate O
therapy O
initiated O
. O

